Faculty Profile

Dr. Matthew J. Akiyama, M.D.

Matthew J. Akiyama, M.D.

Assistant Professor, Department of Medicine (General Internal Medicine)

Areas of Research: I study how people access and utilize hepatitis C treatment and prevention services with particular emphasis on the relationship between HCV, drug use, and the criminal justice system in the U.S. and sub-Saharan Africa.

Professional Interests

Dr. Akiyama is an Assistant Professor of Medicine and Clinician-Investigator, with joint appointments in the Divisions of General Internal Medicine and Infectious Diseases. In addition to providing care and treatment to people living with HIV, hepatitis C virus (HCV), and substance use disorders, Dr. Akiyama conducts research focusing on HCV among socioeconomically marginalized populations with particular emphasis on the intersection of HCV in the criminal justice system and sub-Saharan Africa. Dr. Akiyama is the recipient of a K99/R00 award from the National Institute on Drug Abuse to develop and test an innovative strategy to improve linkage to and retention in HCV treatment among individuals recently released from jail. He is the recipient of additional institutional and NIH funding including an NIDDK P30 pilot grant focused on HCV Transmission Networks Among People Who Inject Drugs. 

Dr. Akiyama completed his Infectious Diseases Fellowship at New York University/Bellevue Hospital Center and a Master of Science in Medical Anthropology at University College London in London, England. 

Selected Awards & Honors

Vice-Chair, Interntional Network on Hepatitis in Substance Users (INHSU) Prisons (2019)

Member, Governor Cuomo’s New York State Hepatitis C Elimination Task Force (2018)

Advisory Board, New York City Department of Health Viral Hepatitis Symposium (2017-2018)

Albert Einstein College of Medicine KL2 Career Development Award (2017)

Co-Chair, Social Determinants, New York State Hepatitis C Elimination Summit (2016-2017)

Selected Publications

Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Hepatitis C Prevalence, Estimated Incidence, Risk Behaviors, and Genotypic Distribution Among People Who Inject Drugs Accessing Harm Reduction Services in Kenya: A Retrospective Cohort Study. Lancet ID. In Press. 

Akiyama MJ, Columbus D, MacDonald R, Jordan AO, Schwartz J, Litwin AH, Eckhardt B, Carmody E. Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial. BMC Infect Dis. 2019 Aug 8;19(1):703.

Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy. Annals of Internal Medicine. 2019 Apr 9.

Spaulding AC, Graham CS, Akiyama MJ, Chhatwal J, Nijhawan AE, Ninburg MH, Rich JD, Strick LB, Taylor LE, Trooskin SB, Westergaard RP, Sabol WJ. HCV prevalence estimates among incarcerated persons. Hepatology. 2019 Apr 2. 

Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am. 2018 Jun;32(2):347-370.

Akiyama MJ, Feffer R, Von Oehsen III WF, Litwin AH. Drug Purchasing Strategies to Treat People With Hepatitis C in the Criminal Justice SystemAJPH. 2018 May;108(5):607-608. 

Akiyama MJ, Agyemang L, Arnsten, JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infect Dis. 2018 Feb 9;18(1):74. 

MacDonald R, Akiyama MJ, Kopolow A, Rosner Z, McGahee W, Joseph R, Jaffer M, Venters H. Full Title: Feasibility of Treating Hepatitis C in a Transient Jail Population. Open Forum Infect Dis2017 Jul 7;4(3):ofx142. 

Akiyama MJ, Kaba F, Rosner Z, Alper H, Kopolow A, Litwin A, Venters H, Macdonald R. Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System: Epidemiologic Patterns and Priorities for Action. Public Health Reports2017 Jan/Feb;132(1):41-47.

Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the “Birth Cohort” (b. 1945-1965) and younger inmates of New York City Jails. AJPH. 2016 Jul;106(7):1276-7.

Feller DJ, Akiyama MJ, Gordon P, Agins BD. Readmissions in HIV-infected Inpatients: A Large Cohort Analysis. JAIDS. 2016 Apr 1;71(4):407-12.

BardfieldJ, Agins B, Akiyama MJ, Mutandi G, Basenero A, Luphala P, Kaindjee-tjituka F, Natanael S, Hamunime N. A Quality Improvement Approach to Capacity Building in Low- and Middle-Income Countries: The case of HEALTHQUAL International. AIDS. 2015 Jul;29 Suppl2:S179-86.  

Vo PK, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virologic Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences 2015 Apr;60(4):1045-51.

Akiyama MJ, Piotrowski JI, Roytman MM, Chan A, Hong LK, Huddleston L, Trujillo R, Tsai N. New Triple Therapy for Chronic Hepatitis C: Real Life Clinical Experience in a Community Setting. Hawaii Journal of Medicine and Public Health 2013 Sep;72(9 Suppl 4):6-13. 


Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Montefiore Medical Group
1621 Eastchester Road
Bronx, NY 10461

Tel: 718.405.8040
Fax: 718.405.8050

Research Information